Collegium Q1 net revenue $144.9M, GAAP net income $27.7M, CEO steps down May 24

COLLEGIUM PHARMACEUTICAL, INC

2024-Q1 EPS reported $0.71 revenue$144,923,000

GAAP net income of $27.7M ($0.71 diluted EPS) vs. loss of $(17.4M) in Q1 2023.
Adjusted EBITDA of $92.4M, up 5% YoY; non-GAAP adjusted EPS of $1.45.
Record Belbuca revenue of $50.7M, up 15% YoY; total prescriptions up 4.2%.
CEO Joe Ciaffoni to step down May 24, 2024; Michael Heffernan named interim CEO.
Board authorized $35M accelerated share repurchase program; reiterated FY2024 guidance.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

COLLEGIUM PHARMACEUTICAL, INC reported the quarter ended March 31, 2024 results: revenue $144.9 million, net income $27.7 million, EPS $0.86 GAAP earnings per share (basic) and $0.71 GAAP earnings per share (diluted). Guidance reaffirmed.

Period: the quarter ended March 31, 2024
Revenue: $144.9 million
Net income: $27.7 million
EPS: $0.86 GAAP earnings per share (basic) and $0.71 GAAP earnings per share (diluted)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

under Item 2.02 of this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Collegium Reports First Quarter 2024 Financial Results – Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca ® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP

View on SEC.gov

1053 earnings releases filed in the last 30 days. Browse all earnings releases →

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001558370-24-007596

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.